Appendix 1—figure 4. Breakdown of the drug classes of positive scoring insulin resistance-drug repurposing (IR-DR) compounds based on their known primary pharmacological actions.

From >250 active compounds, 140 were associated with a positive action on the IR-DR signature and thus predicted to treat IR. Using the pre-assigned pharmacological descriptors of each compound, they were groups into general classes of compound and represented by a pie-chart. Over 45% of the compounds were classed as kinase inhibitors, while the remaining positively acting compounds belonged to a broad range of pharmacological classes